Royal Bank of Canada set a $19.00 price target on Allscripts Healthcare Solutions (NASDAQ:MDRX) in a research note released on Thursday morning. The firm currently has a buy rating on the software maker’s stock.

Several other equities analysts have also issued reports on MDRX. Cantor Fitzgerald reiterated a buy rating and issued a $17.00 price target on shares of Allscripts Healthcare Solutions in a research note on Wednesday, September 27th. Maxim Group reiterated a buy rating and issued a $20.00 price target on shares of Allscripts Healthcare Solutions in a research note on Tuesday, January 9th. Dougherty & Co reiterated a buy rating and issued a $16.00 price target (up previously from $15.00) on shares of Allscripts Healthcare Solutions in a research note on Tuesday, October 3rd. Citigroup assumed coverage on Allscripts Healthcare Solutions in a research note on Thursday, January 4th. They issued a buy rating on the stock. Finally, BidaskClub upgraded Allscripts Healthcare Solutions from a hold rating to a buy rating in a research note on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company’s stock. Allscripts Healthcare Solutions currently has an average rating of Buy and an average price target of $15.53.

Shares of Allscripts Healthcare Solutions (MDRX) traded up $0.09 on Thursday, hitting $16.03. The stock had a trading volume of 1,439,500 shares, compared to its average volume of 1,970,689. Allscripts Healthcare Solutions has a one year low of $11.01 and a one year high of $16.13. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.98 and a current ratio of 0.98. The company has a market cap of $2,900.00, a price-to-earnings ratio of -13.82, a price-to-earnings-growth ratio of 2.27 and a beta of 1.32.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its quarterly earnings results on Thursday, November 2nd. The software maker reported $0.12 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.12. Allscripts Healthcare Solutions had a positive return on equity of 6.53% and a negative net margin of 12.23%. equities analysts expect that Allscripts Healthcare Solutions will post 0.46 earnings per share for the current fiscal year.

In other Allscripts Healthcare Solutions news, EVP Brian Farley sold 5,000 shares of Allscripts Healthcare Solutions stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $14.35, for a total transaction of $71,750.00. Following the transaction, the executive vice president now directly owns 191,607 shares of the company’s stock, valued at approximately $2,749,560.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP James Hewitt sold 36,796 shares of Allscripts Healthcare Solutions stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $14.11, for a total value of $519,191.56. Following the transaction, the senior vice president now directly owns 181,766 shares in the company, valued at $2,564,718.26. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,796 shares of company stock worth $804,842. 0.91% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in Allscripts Healthcare Solutions by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 14,824,640 shares of the software maker’s stock worth $189,162,000 after buying an additional 181,721 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Allscripts Healthcare Solutions by 3.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 9,508,667 shares of the software maker’s stock worth $135,308,000 after buying an additional 337,382 shares during the period. Fiduciary Management Inc. WI lifted its holdings in Allscripts Healthcare Solutions by 0.6% during the 2nd quarter. Fiduciary Management Inc. WI now owns 6,083,536 shares of the software maker’s stock worth $77,626,000 after buying an additional 38,426 shares during the period. State Street Corp lifted its holdings in Allscripts Healthcare Solutions by 28.6% during the 2nd quarter. State Street Corp now owns 5,975,551 shares of the software maker’s stock worth $76,251,000 after buying an additional 1,330,721 shares during the period. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in Allscripts Healthcare Solutions by 1.0% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 5,062,035 shares of the software maker’s stock worth $72,033,000 after buying an additional 49,823 shares during the period.

TRADEMARK VIOLATION NOTICE: “Royal Bank of Canada Reiterates $19.00 Price Target for Allscripts Healthcare Solutions (MDRX)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/01/15/royal-bank-of-canada-reiterates-19-00-price-target-for-allscripts-healthcare-solutions-mdrx.html.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.